Investors once again lined up behind a potentially revolutionary cancer diagnostic being developed by Thrive Earlier Detection Corp.
The one-year-old start up raised a $257 million Series B round from a syndicate of venture and crossover investors, including round leaders Casdin Capital and Section 32 and new investors Bain Capital Life Sciences, Brown Advisory, Driehaus Capital Management, Intermountain Ventures, Janus Henderson Investors, Lux Capital, Moore Strategic Ventures, Perceptive Advisors, Rock Springs Capital, Sands Capital, funds and accounts advised by T. Rowe Price Associates, Inc., and other undisclosed investors.
The new round is more than double the $110 million Series A round raised by the company last May. The company said all of its first-round investors participated in the new financing including Casdin, Biomatics, Third Rock Ventures, BlueCross BlueShield Venture Partners, Invus, Exact Sciences, Cowin Venture, Camden Partners, Gamma 3 LLC …